Article
Biochemistry & Molecular Biology
Jessica A. Martinez, Betsy C. Wertheim, Denise J. Roe, Mihra S. Taljanovic, H-H. Sherry Chow, Wade Chew, Sima Ehsani, Sao Jiralerspong, Jennifer Segar, Pavani Chalasani
Summary: This prospective study investigates the inflammatory metabolomic changes in the development of aromatase inhibitor-induced arthralgia (AIA). The results suggest that the oxylipin 8-HETE could be a potential biomarker for AIA.
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Angeliki Andrikopoulou, Oraianthi Fiste, Michalis Liontos, Meletios-Athanasios Dimopoulos, Flora Zagouri
Summary: The use of CDK4/6 inhibitors in breast cancer patients may reduce musculoskeletal symptoms induced by AI treatment, including arthralgia, myalgias, back pain, and bone pain, but further studies are needed to confirm their effectiveness.
Article
Medicine, General & Internal
Jessica A. Martinez, Mihra S. Taljanovic, Andres A. Nuncio Zuniga, Betsy C. Wertheim, Denise J. Roe, Sima Ehsani, Sao Jiralerspong, Jennifer Segar, Pavani Chalasani
Summary: Aromatase inhibitor-induced arthralgia (AIA) is characterized by significant musculoskeletal symptoms such as joint pain, myalgia, and joint stiffness. A prospective study conducted on postmenopausal women with early-stage hormone receptor positive (HR+) breast cancer found that changes in tendon and median nerve velocities were associated with pain and stiffness levels. Higher velocities were linked to greater pain, while slower velocities were associated with higher stiffness scores. Increased velocity in the abductor pollicis longus tendon was found to be related to worsened pain and stiffness measures.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Sara Caceres, Beatriz Monsalve, Angela Alonso-Diez, Belen Crespo, Maria Jose Illera, Paloma Jimena de Andres, Gema Silvan, Juan Carlos Illera
Summary: Through experimental studies on canine and human inflammatory breast cancer, it was found that anti-aromatase and anti-sulfatase therapies have inhibitory effects on tumors in vitro, while anti-sulfatase can increase tumor progression; letrozole effectively reduces tumor progression by decreasing estrogen levels.
Article
Radiology, Nuclear Medicine & Medical Imaging
Su Hyun Lee, Myoung-jin Jang, Heera Yoen, Youkyoung Lee, Yeon Soo Kim, Ah Reum Park, Su Min Ha, Soo-Yeon Kim, Jung Min Chang, Nariya Cho, Woo Kyung Moon
Summary: Background parenchymal enhancement (BPE) at surveillance breast MRI is associated with future second breast cancer risk in women with a personal history of breast cancer.
Review
Oncology
Xiaomeng Liu, Jing Lu, Guoxin Wang, Xiu Chen, Haiping Xv, Jing Huang, Mingxin Xue, Jinhai Tang
Summary: This meta-analysis confirms the effectiveness and safety of acupuncture in treating aromatase inhibitor-induced arthralgia in breast cancer patients, with significant improvements in pain-related interference, pain severity, and worst pain. Further research is needed to explore the specific and placebo effects of acupuncture.
INTEGRATIVE CANCER THERAPIES
(2021)
Review
Medicine, General & Internal
Kamila Boszkiewicz, Agnieszka Piwowar, Pawel Petryszyn
Summary: Aromatase inhibitors (AIs) are commonly used as first-line therapy for hormone-dependent breast cancer patients. However, their use is associated with increased risk of cardiovascular events and the development of insulin resistance and diabetes. This meta-analysis found that AIs are associated with a higher risk of cardiovascular events compared to tamoxifen (TAM), but no significant association was found with hypertension, dyslipidemia, hyperglycemia, or weight gain.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Chia-Lin Tsai, Liang-Chih Liu, Chih-Ying Liao, Wen-Ling Liao, Yu-Huei Liu, Ching-Liang Hsieh
Summary: This study aimed to evaluate the therapeutic effects of yoga and massage on AI-associated knee joint pain. The results showed that yoga was more effective than massage for reducing AI-associated knee joint pain.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Jing Xu, Bo Cao, Chunyu Li, Guohui Li
Summary: Breast cancer is a global health concern. Endocrine therapy is crucial in treating estrogen-positive breast cancer, but it often leads to osteoporosis-related adverse events. These events increase the risk of fractures and reduce the patients' quality of life. This review explores the possibility of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer treatment and discusses the mechanisms involved and the potential of drug therapies and combinations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mina Shenouda, Renee Copley, Toni Pacioles, Yehuda Lebowicz, Muhammad Jamil, Sutoidem Akpanudo, Maria Tria Tirona
Summary: Aromatase inhibitor induced arthralgia (AIA) can decrease compliance and breast cancer survival. Tart cherry (TC) has shown beneficial effects on musculoskeletal pain and can improve AIA in non-metastatic breast cancer patients.
CLINICAL BREAST CANCER
(2022)
Article
Oncology
Molly B. Moravek, Rafael Confino, Angela K. Lawson, Kristin N. Smith, Ralph R. Kazer, Susan C. Klock, William J. Gradishar, Jacqueline S. Jeruss, Mary Ellen Pavone
Summary: The study compared recurrence and survival in breast cancer patients who pursued fertility preservation (FP) and those who did not, finding that regardless of receptor status, patients undergoing FP had similar outcomes. Age and parity were the main factors influencing the likelihood of pursuing FP, and breast cancer stage had minimal impact on this decision.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Chemistry, Medicinal
Amit Kumar Jana, Jyotsana Singh, Asha Ganesher, Amit Kumar, Arpita Banerjee, Deepak Kumar, Sarvesh Kumar Verma, Ashok Kumar Sharma, Rabi Sankar Bhatta, Rituraj Konwar, Gautam Panda
Summary: A new chemical entity, benzoxazine, was designed for improving anti-breast cancer activity. Compound 13d, as a lead compound, induced apoptosis, cell cycle arrest, and loss of mitochondrial membrane potential in breast cancer cells. In a rat syngenic mammary tumor model, both 13d and 13d-f showed significant tumor regression without causing any mortality.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)